ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Clinical trials for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE explained in plain language.
Never miss a new study
Get alerted when new ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE trials appear
Sign up with your email to follow new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to supercharge Cancer-Fighting cells in tough leukemia cases
Disease control Recruiting nowThis study tests whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Participants will be randomly assigned to receive either standard c…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 26, 2026 11:56 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment using specially engineered immune cells (CD7 CAR T-cells) for people with T-cell cancers that have come back or not responded to standard therapy. The cells are made from the patient's own blood or from a donor. The goal is to see if this treatmen…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 26, 2026 11:56 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD5 CAR-T cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells (or cells from a donor) that are specially trained to find and attack cancer ce…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 26, 2026 11:48 UTC
-
New CAR T-Cell therapy offers hope for kids with Tough-to-Treat leukemia
Disease control Recruiting nowThis study tests a new treatment for children and young adults (up to age 21) with a type of leukemia (CD19-positive) that has returned or not responded to standard therapy. The treatment uses specially engineered immune cells from a family donor to attack the cancer. The main go…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 26, 2026 11:46 UTC
-
Supercharged immune cells take on tough blood cancers
Disease control Recruiting nowThis early-phase trial tests a personalized therapy where a patient's own immune cells are genetically modified to recognize and attack cancer cells. It is for children and adults with certain blood cancers (like leukemia or lymphoma) that have not responded to standard treatment…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Nelson Hamerschlak • Aim: Disease control
Last updated May 26, 2026 10:35 UTC
-
New CAR T-Cell combo shows promise against tough leukemia
Disease control Recruiting nowThis study tests two different CAR T-cell therapy approaches for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. One group gets a combination of two types of CAR T-cells (CD19 and CD22), while the other gets one type (CD19) follow…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New nanobody CAR t therapy targets tough T-Cell cancers in early trial
Disease control Recruiting nowThis study tests a new treatment called nanobody CD5-CAR T cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and attack cancer ce…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New combo therapy offers hope for kids with Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a combination of the targeted drug trametinib with standard chemotherapy drugs in children and young adults up to age 21 whose leukemia or lymphoma has returned or not responded to treatment. The goal is to find the safest dose and see if the combination can shri…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Donor immune cells target hard-to-treat leukemia in new safety trial
Disease control Recruiting nowThis study tests a two-step treatment for people with a type of leukemia that has come back or not responded to standard care. First, participants receive donor immune cells (CAR T cells) that target a protein called CD19 on cancer cells, followed by a stem cell transplant from t…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Promising drug cocktail targets tough childhood leukemias
Disease control Recruiting nowThis study tests a combination of two targeted drugs (ruxolitinib and venetoclax) plus standard chemotherapy in children and young adults with relapsed or hard-to-treat acute lymphoblastic leukemia or lymphoma. The goal is to find the safest dose and see how well the treatment sh…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New combo therapy aims to tackle tough blood cancers in kids
Disease control Recruiting nowThis early-phase study tests a drug called venetoclax combined with standard chemotherapy for children, teens, and young adults with aggressive blood cancers like leukemia and myelodysplastic syndrome. The goal is to find the safest dose and understand side effects. About 30 part…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Andrew E. Place, MD • Aim: Disease control
Last updated May 14, 2026 12:03 UTC